Cardiovascular Biotherapeutics (CVBT) 8-K CardioVascular BioTherapeutics, Inc. Completes Note Conversions

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

April 25, 2005

CardioVascular BioTherapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	333-119199	33-0795984
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1700 West Horizon Ridge Parkway, Suite 100

Henderson, Nevada

89012

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: 702-248-1174

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02	Results of Operations and Financial Condition
	CardioVascular BioTherapeutics, Inc. announced in a press release on April 19, 2005 it concluded the conversion of $14,872,200 of convertible notes into 5,782,550 shares of its common stock.
	A copy of this press release is furnished as Exhibit 99.1 to this report. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any filing of the company, whether made before or after the date of this report, regardless of any general incorporation language in the filing.
Item 9.01	Financial Statements and Exhibits
(c)	Exhibits
	99.1	Press Release dated April 19, 2005 announcing CardioVascular BioTherapeutics, Inc. concluded the conversion of $14,872,200 of convertible notes into 5,782,550 shares of its common stock.

-2-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CARDIOVASCULAR BIOTHERAPEUTICS, INC.
Date: April 25, 2005	By:	/s/ Mickael A. Flaa
		Michael A. Flaa
		Chief Financial Officer

-3-

EXHIBIT INDEX

99.1 Press Release dated April 19, 2005 announcing CardioVascular BioTherapeutics, Inc. concluded the conversion of $14,872,200 of convertible notes into 5,782,550 shares of its common stock.

-4-